UroGen Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	109.79	90.4	82.71	64.36	48.04
Revenue Growth (YoY)	21.45%	9.29%	28.52%	33.96%	307.17%
Cost of Revenue	12.45	8.88	9.36	7.65	5.16
Gross Profit	97.34	81.52	73.35	56.7	42.89
Selling, General & Admin	155.1	121.15	93.27	82.84	87.54
Research & Development	67.11	57.15	45.61	52.91	47.64
Total Operating Expenses	222.2	178.3	138.89	135.74	135.18
Operating Income	-124.86	-96.78	-65.54	-79.04	-92.29
Total Non-Operating Income (Expense)	-28.55	-27.26	-32.79	-28.99	-17.08
Pretax Income	-153.42	-124.04	-98.32	-108.03	-109.37
Provision for Income Taxes	0.08	2.83	3.92	1.76	1.45
Net Income	-153.49	-126.87	-102.24	-109.78	-110.82
Net Income to Common	-153.49	-126.87	-102.24	-109.78	-110.82
Shares Outstanding (Basic)	48	43	29	23	22
Shares Outstanding (Diluted)	48	43	29	23	22
Shares Change (YoY)	12.22%	48.70%	26.43%	2.05%	2.60%
EPS (Basic)	-3.19	-2.96	-3.55	-4.81	-4.96
EPS (Diluted)	-3.19	-2.96	-3.55	-4.81	-4.96
Free Cash Flow	-162.73	-97.06	-76.57	-87.81	-85.64
Free Cash Flow Per Share	-3.38	-2.26	-2.66	-3.85	-3.83
Gross Margin	88.66%	90.18%	88.68%	88.11%	89.27%
Operating Margin	-113.73%	-107.06%	-79.23%	-122.82%	-192.11%
Profit Margin	-139.81%	-140.35%	-123.61%	-170.58%	-230.67%
FCF Margin	-148.22%	-107.37%	-92.57%	-136.45%	-178.27%
EBITDA	-124.56	-96.45	-64.73	-78.12	-91.46
EBITDA Margin	-113.45%	-106.70%	-78.26%	-121.38%	-190.38%
EBIT	-124.86	-96.78	-65.54	-79.04	-92.29
EBIT Margin	-113.73%	-107.06%	-79.23%	-122.82%	-192.11%
Effective Tax Rate	-0.05%	-2.28%	-3.99%	-1.62%	-1.32%

Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q